|1.||Kim, Sinil: 28 articles (08/2015 - 11/2007)|
|2.||Rini, Brian I: 15 articles (12/2015 - 12/2005)|
|3.||Bycott, Paul: 15 articles (05/2015 - 07/2006)|
|4.||Rosbrook, Brad: 13 articles (12/2015 - 09/2009)|
|5.||Pithavala, Yazdi K: 13 articles (04/2015 - 08/2005)|
|6.||Tarazi, Jamal: 12 articles (12/2015 - 09/2009)|
|7.||Rixe, Olivier: 10 articles (01/2015 - 11/2007)|
|8.||Motzer, Robert J: 9 articles (12/2015 - 11/2007)|
|9.||Escudier, Bernard: 8 articles (12/2015 - 01/2011)|
|10.||Chen, Connie: 8 articles (01/2015 - 12/2011)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2015 - "Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma."
08/01/2015 - "Re: Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma."
07/01/2015 - "In a randomized, double-blind phase II trial in patients with metastatic renal cell carcinoma (mRCC), axitinib versus placebo titration yielded a significantly higher objective response rate. "
07/01/2015 - "Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma."
04/01/2015 - "Ambulatory BP monitoring (ABPM) and pharmacokinetic data were collected in a randomised, double-blind phase II study of axitinib with or without dose titration in previously untreated patients with metastatic renal cell carcinoma. "
01/01/2015 - "In contrast, axitinib treatment was effective in inhibiting angiogenesis and tumor growth in both models, with its antitumor effect significantly increased by the combined treatment with crizotinib, independently from c-met expression. "
04/01/2014 - "Axitinib radiosensitizes tumor endothelial cells and enhances tumor cure with SDRT, which may permit dose de-escalation and significantly expand the range of clinical indications for SDRT."
01/01/2012 - "We evaluated the effect of axitinib on targeting cancer stemlike cells and enhancing the efficacy of chemotherapeutical agents. "
01/01/2012 - "Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2."
12/01/2015 - "Long-term safety with single-agent axitinib was analyzed using pooled data from clinical trials in 672 previously treated patients with metastatic RCC (mRCC) and in 1304 patients with different advanced solid tumors. "
|3.||Melanoma (Melanoma, Malignant)
12/01/2011 - "Axitinib was well tolerated, showed a selective VEGFR-inhibitory profile, and showed single-agent activity in metastatic melanoma. "
12/01/2014 - "The final analysis indicated that the pharmacokinetic model for mRCC was able to successfully describe axitinib pharmacokinetics in patients with NSCLC, thyroid cancer, and melanoma. "
06/01/2012 - "On the basis of the reported ability of axitinib to 'normalize' the tumor vasculature, we hypothesize that combination therapy using axitinib plus specific peptide-based vaccination would promote superior activation and recruitment of protective T cells into the melanoma microenvironment, leading to enhanced treatment benefit. "
06/01/2012 - "Using a subcutaneous M05 (B16.OVA) melanoma model, we observed that a treatment regimen consisting of a 7-day course of axitinib (0.5 mg/day provided orally) combined with a subcutaneous vaccine [ovalbumin (OVA) peptide-pulsed syngenic dendritic cells adenovirally engineered to produce IL-12p70] yielded superior protection against melanoma growth and extended overall survival when compared with animals receiving either single modality therapy. "
12/01/2011 - "This multicenter, open-label, phase II study evaluated the safety and clinical activity of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, 2, and 3, in patients with metastatic melanoma. "
|4.||Hypertension (High Blood Pressure)
12/03/2011 - "Axitinib dose increases to 7 mg and then to 10 mg, twice daily, were allowed for those patients without hypertension or adverse reactions above grade 2. Participants were not masked to study treatment. "
12/01/2015 - "Most common all-causality adverse events with axitinib/BSC were diarrhoea (54%), hypertension (54%), and decreased appetite (47%). "
03/01/2015 - "Recommendations for monitoring blood pressure and managing hypertension during axitinib therapy are presented. "
03/01/2015 - "Hypertension-related sequelae occurred in <1 % of axitinib-treated patients. "
03/01/2015 - "Approximately 50 % of axitinib-treated patients with grade 3 or 4 hypertension continued treatment for ≥ 9 months. "
|5.||Thyroid Neoplasms (Thyroid Cancer)
12/01/2014 - "Axitinib may be useful for the treatment of advanced thyroid cancer."
12/01/2014 - "A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses."
09/01/2014 - "In a previous phase 2 trial, axitinib was active and well tolerated in patients with advanced thyroid cancer. "
09/01/2014 - "Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments."
01/01/2009 - "To date, in phase II clinical studies axitinib has demonstrated antitumor activity in advanced refractory thyroid cancer. "
|1.||sorafenib (BAY 43-9006)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|6.||axitinib (AG 013736)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)